Oncoinvent ASA
ONCIN
Rang in Aktien
#27231
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Aktienkurs
$7.06
Marktkapitalisierung
$31.63M
Veränderung (1 Tag)
-1.19%
Veränderung (1 Jahr)
6,305.84%
Land
NO
Handel Oncoinvent ASA (ONCIN)
Kategorie
Healthcare
Kursverlauf für Oncoinvent ASA (ONCIN)
Höchster Schlusskurs: $9.10 am 2026-09-01
Niedrigster Schlusskurs: $27.86 am 2017-12-01
Niedrigster Schlusskurs: $27.86 am 2017-12-01
Kursverlauf der Aktie von Oncoinvent ASA von 2017 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 268.35% |
| 2025 | 32.73% |
| 2024 | -64.40% |
| 2023 | -90.91% |
| 2022 | 4.70% |
| 2021 | -41.35% |
| 2020 | 114.55% |
| 2019 | -57.70% |
| 2018 | 64.64% |
| 2017 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.24 | 7.63% |
CH
|
